US 12,486,271 B2
Solid forms of a toll-like receptor modulator
Brandon Heath Brown, Burlingame, CA (US); and Paul A. Roethle, Berkeley, CA (US)
Assigned to Gilead Sciences, Inc., Foster City, CA (US)
Filed by GILEAD SCIENCES, INC., Foster City, CA (US)
Filed on Aug. 17, 2023, as Appl. No. 18/451,611.
Application 18/451,611 is a continuation of application No. 17/353,462, filed on Jun. 21, 2021, granted, now 11,773,098.
Application 17/353,462 is a continuation of application No. 16/678,788, filed on Nov. 8, 2019, granted, now 11,072,615, issued on Jul. 27, 2021.
Application 16/678,788 is a continuation of application No. 16/229,460, filed on Dec. 21, 2018, granted, now 10,508,117, issued on Dec. 17, 2019.
Application 16/229,460 is a continuation of application No. 15/591,711, filed on May 10, 2017, granted, now 10,202,384, issued on Feb. 19, 2019.
Application 15/591,711 is a continuation of application No. 14/853,855, filed on Sep. 14, 2015, granted, now 9,738,646, issued on Aug. 22, 2017.
Claims priority of provisional application 62/051,063, filed on Sep. 16, 2014.
Prior Publication US 2024/0217975 A1, Jul. 4, 2024
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 31/519 (2006.01); A61K 45/06 (2006.01); A61P 31/18 (2006.01); C07D 475/06 (2006.01); C07D 487/04 (2006.01)
CPC C07D 475/06 (2013.01) [A61K 31/519 (2013.01); A61K 45/06 (2013.01); C07D 487/04 (2013.01)] 20 Claims
 
1. A method of treating HIV in a human in need thereof, the method comprising administering to the human a therapeutically effective amount of a crystalline form of Compound I having the structure:

OG Complex Work Unit Chemistry
characterized by an X-ray powder diffraction (XRPD) pattern comprising peaks at 5.8, 11.6, and 22.3 degrees 2θ (±0.2 degrees 2θ), wherein the XRPD is made using CuKα1 radiation.